- Home
- SEED vs ICCM Comparison
SEED vs ICCM Comparison
Compare SEED & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SEED | ICCM |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7M | 45.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SEED | ICCM |
|---|---|---|
| Price | $1.16 | $0.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 40.6K | ★ 353.1K |
| Earning Date | 02-09-2026 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,910,081.00 | $2,975,000.00 |
| Revenue This Year | N/A | $13.67 |
| Revenue Next Year | N/A | $38.55 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.74 | $0.59 |
| 52 Week High | $2.70 | $1.66 |
Technical Indicators
Market Signals| Indicator | SEED | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 36.93 | 42.17 |
| Support Level | $1.25 | $0.65 |
| Resistance Level | $1.33 | $0.68 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 9.49 | 39.16 |
Price Performance
Historical ComparisonAbout SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.